Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.

@article{Ornbjerg2013ImpactOT,
  title={Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.},
  author={Lykke Midtb\oll Ornbjerg and Mikkel Ostergaard and Pernille B\oyesen and Niels Steen Krogh and Anja Thormann and Ulrik Tarp and Uta Engling Poulsen and Jakob Espesen and Vibeke Stevenius Ringsdal and Niels Albert Graudal and Gina Birgitte Kollerup and Dorte Vendelbo Jensen and Ole Rintek Madsen and Bente Glintborg and Torben Grube Christensen and Hanne Merete Lindegaard and Ditte Dencker and Annette Hansen and Anne R\odgaard Andersen and Merete Lund Hetland},
  journal={Annals of the rheumatic diseases},
  year={2013},
  volume={72 1},
  pages={57-63}
}
OBJECTIVES To compare radiographic progression during treatment with disease-modifying antirheumatic drugs (DMARD) and subsequent treatment with tumour necrosis factor α inhibitors (TNF-I) in rheumatoid arthritis (RA) patients in clinical practice. METHODS Conventional radiographs (x-rays) of hands and wrists were obtained ∼2 years before start (prebaseline), at baseline and ∼2 years after start (follow-up) of TNF-I. Clinical data were obtained from the DANBIO registry and the patient files… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
To compare radiographic progression during treatment with disease - modifying antirheumatic drugs ( DMARD ) and subsequent treatment with tumour necrosis factor α inhibitors ( TNF - I ) in rheumatoid arthritis ( RA ) patients in clinical practice .
Patients were treated with infliximab ( 61% ) , etanercept ( 15% ) or adalimumab ( 24% ) .
Patients were treated with infliximab ( 61% ) , etanercept ( 15% ) or adalimumab ( 24% ) .
Patients were treated with infliximab ( 61% ) , etanercept ( 15% ) or adalimumab ( 24% ) .
Patients were treated with infliximab ( 61% ) , etanercept ( 15% ) or adalimumab ( 24% ) .
Patients were treated with infliximab ( 61% ) , etanercept ( 15% ) or adalimumab ( 24% ) .
Patients were treated with infliximab ( 61% ) , etanercept ( 15% ) or adalimumab ( 24% ) .
All Topics